Loading
CRISPR and Genetic Engineering / Mosquito Borne Diseases and Control · Journal article
Viruses · September 3, 2026
Raises a question worth testing. It does not answer one.
This narrative review discusses CCR5 as a therapeutic target for HIV via two complementary approaches—CRISPR/Cas9-mediated gene editing and maraviroc-mediated receptor blockade—and proposes their potential roles in combination therapies for functional cure. The source presents conceptual and preclinical evidence without reporting a primary clinical trial result, efficacy measure, or comparative endpoint data.
Journal article. Individuals with HIV-1 infection and carriers of CCR5Δ32 mutation; broader context of HIV cure research.
CCR5Δ32 mutation confers marked resistance to HIV infection, establishing rationale for CCR5 inhibition as both genetic and pharmacological strategy CRISPR/Cas9-mediated CCR5 disruption and multiplex editing strategies designed to overcome viral tropism switching are discussed as emerging approaches Maraviroc exhibits potential immunomodulatory effects, latency-reversing activity, and applications beyond viral entry inhibition in graft-versus-host disease and cancer
CCR5Δ32 mutation confers marked resistance to HIV infection, establishing rationale for CCR5 inhibition as both genetic and pharmacological strategy
Clinicians and researchers should recognize this review as a synthesis of therapeutic concepts rather than evidence sufficient to change practice. The proposed complementary role of CCR5-targeted interventions in combination therapy remains at the stage of preclinical and emerging clinical exploration.
This is a narrative review synthesizing mechanistic concepts and emerging data on CCR5-targeted approaches; it raises questions about therapeutic potential rather than reporting a definitive trial result or meta-analysis.
Clinicians and researchers should recognize this review as a synthesis of therapeutic concepts rather than evidence sufficient to change practice. The proposed complementary role of CCR5-targeted interventions in combination therapy remains at the stage of preclinical and emerging clinical exploration.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The C-C chemokine receptor type 5 (CCR5) is the principal co-receptor for R5-tropic HIV-1 and remains one of the most promising therapeutic targets in the pursuit of an HIV cure. The discovery that individuals carrying the naturally occurring CCR5Δ32 mutation exhibit marked resistance to HIV infection established the foundation for both genetic and pharmacological approaches to CCR5 inhibition. This review summarizes recent advances in CCR5-targeted therapies with a focus on CRISPR/Cas9-mediated gene editing and maraviroc-mediated receptor blockade. We discuss the molecular mechanisms, preclinical evidence and emerging clinical data supporting CRISPR-based CCR5 disruption, including multiplex editing strategies designed to overcome viral tropism switching. We also examine the evolving role of maraviroc beyond viral entry inhibition, highlighting its immunomodulatory effects, potential latency-reversing activity and applications in graft-versus-host disease and cancer. Together, these complementary strategies underscore the potential of CCR5-targeted interventions as integral components of future combination therapies aimed at achieving durable HIV remission or functional cure.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.